Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion

Background. Sorafenib, an oral tyrosine kinase inhibitor (TKI), targets multiple tyrosine kinase receptors (TKRs) involved in angiogenesis and tumor growth. Studies suggest that inhibition of TKR impacts cardiomyocyte survival. Inhibition of VEGF signaling interrupts angiogenesis and is associated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Candace, Shemisa, Kamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425844/
https://www.ncbi.nlm.nih.gov/pubmed/28536660
http://dx.doi.org/10.1155/2017/7065759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425844/
https://www.ncbi.nlm.nih.gov/pubmed/28536660
http://dx.doi.org/10.1155/2017/7065759

Ejemplares similares